The chronic nature of the disease, which requires ongoing treatment, and the relatively high annual cost of therapy (ACoT) have made RA treatment a highly lucrative market...
To know more, click on the link below:
https://www.kenresearch.com/healthcare/general-healthcare/rheumatoid-arthritis-therapeutics-in-asia-pacific-markets-to-2023-novel-jak-and-il-6-receptor-inhibitors-to-stimulate-moderate-growth-despite-launch-of-biosimilars-of-blockbuster-anti-tnfs/149110-91.html Еще
